R R

What Is Relugolix?

Relugolix is a prescription gonadotropin-releasing hormone receptor antagonist used to treat advanced prostate cancer in adults. The single-ingredient oral product is marketed under the brand name Orgovyx. It lowers testosterone production, which can help slow the growth of prostate cancers that depend on male hormones. Relugolix is taken orally once daily after an initial loading dose. It differs from injectable hormonal therapies because it directly blocks gonadotropin-releasing hormone receptors and does not initially stimulate testosterone production. Relugolix is also an ingredient in the combination product Myfembree, which has different approved indications and dosing instructions.

Link to This Resource Page

Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.

To display this...

What Is Relugolix?

Relugolix is a prescription gonadotropin-releasing hormone receptor antagonist used to treat advanced prostate cancer in adults. The single-ingredient oral product is marketed under the brand name Orgovyx. It lowers testosterone production, which can help slow the growth of prostate cancers that depend on male hormones. Relugolix is taken orally once daily after an initial loading dose. It differs from injectable hormonal therapies because it directly blocks gonadotropin-releasing hormone receptors and does not initially stimulate testosterone production. Relugolix is also an ingredient in the combination product Myfembree, which has different approved indications and dosing instructions.

read more about relugolix ...

Copy this HTML:

Copy HTML Copied!

How Does Relugolix Work?

Relugolix binds to and blocks gonadotropin-releasing hormone receptors in the pituitary gland. This decreases the release of luteinizing hormone and follicle-stimulating hormone, reducing testosterone production by the testes. Lower testosterone levels can slow the growth of hormone-sensitive prostate cancer cells. Unlike some gonadotropin-releasing hormone agonists, relugolix does not cause an initial testosterone surge before suppression develops. Its effects depend on consistent dosing, and testosterone levels can recover after treatment is discontinued. Relugolix controls hormonal signaling involved in prostate cancer but does not cure the disease.

What Condition Does Relugolix Treat?

Single-ingredient relugolix, marketed as Orgovyx, is FDA-approved for adults with advanced prostate cancer. It provides androgen deprivation therapy by lowering circulating testosterone to castration-level concentrations. A cancer specialist considers disease stage, prior treatments, cardiovascular history, medication interactions, and the patient's treatment goals before prescribing it. Relugolix may be used within a broader prostate cancer treatment plan, including other cancer therapies when appropriate. The combination medication containing relugolix, estradiol, and norethindrone acetate has separate indications involving selected gynecologic conditions and should not be confused with Orgovyx.

How Should Relugolix Be Taken?

Orgovyx treatment begins with a loading dose of 360 mg, taken as three 120 mg tablets on the first day. The patient then takes 120 mg orally once daily at approximately the same time each day, with or without food. Tablets should be swallowed whole rather than crushed or chewed. If a dose is missed by more than 12 hours, it should be skipped. If treatment is interrupted for more than seven days, a new loading dose is required before resuming daily treatment. Oral P-glycoprotein inhibitors and certain strong enzyme-inducing medications may require avoidance, dose separation, or adjustment. Patients should follow the oncology team's monitoring schedule.

What Are the Side Effects and Warnings of Relugolix?

Common adverse effects include hot flashes, fatigue, constipation, diarrhea, joint pain, and reduced sexual function. Laboratory changes may include elevated blood glucose, increased triglycerides, and reduced hemoglobin levels. Relugolix can prolong the QT interval indirectly through testosterone suppression, creating concerns for patients with certain cardiovascular conditions or interacting medications. It can also harm a developing fetus, and patients with partners who can become pregnant should follow contraception recommendations during treatment and for two weeks after the final dose. Clinicians monitor treatment response and testosterone levels when indicated. Palpitations, fainting, severe weakness, or other concerning symptoms require medical evaluation.

Common Questions About Relugolix

Is relugolix the same as Orgovyx?

Yes. Orgovyx is the brand name for single-ingredient relugolix tablets approved to treat advanced prostate cancer in adults.

How does relugolix lower testosterone?

Relugolix blocks pituitary gonadotropin-releasing hormone receptors, reducing hormonal signals that stimulate testosterone production.

Is relugolix the same as Myfembree?

No. Myfembree combines relugolix with estradiol and norethindrone acetate and has different approved uses than single-ingredient Orgovyx.

Does relugolix require a loading dose?

Yes. Orgovyx starts with 360 mg on the first day, followed by 120 mg once daily. A new loading dose is also required after certain extended treatment interruptions.

References

DailyMed - ORGOVYX (relugolix) tablet, film coated. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=077a92f6-9f1b-479a-87c7-c92b5db6aa9c. Date Accessed November 3, 2026.

Relugolix. LiverTox. https://www.ncbi.nlm.nih.gov/books/NBK592663/. Date Accessed November 3, 2026.

Relugolix. MedlinePlus. https://medlineplus.gov/druginfo/meds/a621006.html. Date Accessed November 3, 2026.

Relugolix. PubChem. https://pubchem.ncbi.nlm.nih.gov/compound/Relugolix. Date Accessed November 3, 2026.

Relugolix Therapy for Advanced Prostate Cancer. The New England Journal of Medicine. https://pubmed.ncbi.nlm.nih.gov/32469183/. Date Accessed November 3, 2026.